Telo Therapeutics, Inc.

Telo Therapeutics, Inc. is an oncology therapeutics company established in 2015. With the slogan "Deploying targeted protein degradation to unlock the full potential of nuclear transport inhibitors in oncology," the company aims to significantly enhance the survival and well-being of cancer patients who have exhausted their treatment options. Their focus lies in developing orally bioavailable next-generation inhibitors of nuclear transport, which serves as a critical nexus among various cancer cell signaling pathways. Their development candidate, TSM74, stands out as a novel targeted protein degrader of XPO1, a clinically validated oncology target relevant to a wide range of solid and hematological cancers. Notably, TSM74 demonstrates a vastly improved safety profile compared to existing toxic covalent inhibitors, leading to rapid tumor regressions and complete tumor removal across multiple preclinical cancer models. Recently, Telo Therapeutics secured a $4.71M Seed Round investment on 22 June 2021 with Viva BioInnovator as the investor. The company operates in the Biotechnology and Health and Wellness industries, positioning itself at the forefront of developing innovative treatments for cancer.